TangGene was co-founded by world-renowned immunologists Dr. Harvey Cantor (Harvard Medical School) and Dr. Xiaolei Tang, together with accomplished business executive and investor Jinfeng Tang. We are pioneering the first-in-class precision in vivo CD8+ Treg cell therapy, enabled by a proprietary nanoparticle platform designed to reset immune tolerance and cure autoimmune diseases. Our lead program in Multiple Sclerosis (MS) has demonstrated preclinical data suggesting the potential for full recovery and prevention of disease reinduction. Beyond MS, our pipeline extends to Rheumatoid Arthritis (RA), Type 1 Diabetes (T1D), Inflammatory Bowel Disease (IBD), and Lupus - leveraging a platform engineered for tissue-specific targeting, off-the-shelf scalability, and durable therapeutic benefits.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2024
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was TangGene founded?
TangGene was founded in 2024.
What industry is TangGene in?
TangGene operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is TangGene based?
TangGene is headquartered in Cranbury, United States.
Find investors for your startup like TangGene
Gritt sends AI-personalised outreach to each investor — from your Gmail
